Wave Life Sciences Reports Fourth Quarter and Full Year 2019 Financial Results and Provides Business Update
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/9/2026
- After-Hours Movers: COO, AEO, NAVN, AVAV, TORO
- After-Hours Movers: LULU, IOT, PATH, DOCU, ASAN, GWRE, ZS, PL, SWBI, OXM
- After-Hours Movers: AVGO, SNOW, HPE, NTAP, NTSK, CHPT, FIVE, TLYS, PVH, RARE
- After-Hours Movers: DELL, PANW, GTLB, CRDO, MDB, HPE, SMCI
- After-Hours Movers: WDAY, ADSK, S, RBRK, MRVL, ULTA, GAP, AFRM
WAVE Life Sciences (WVE) Misses Q2 EPS by 22c, Revenues Miss
March 2, 2020 6:46 AM ESTWAVE Life Sciences (NASDAQ: WVE) reported Q2 EPS of ($1.65), $0.22 worse than the analyst estimate of ($1.43). Revenue for the quarter came in at $2.4 million versus the consensus estimate of $5.52 million.
We continue to advance our innovative, CNS-focused pipeline of stereopure oligonucleotides across Huntingtons disease, amyotrophic lateral sclerosis, frontotemporal dementia and other central nervous system diseases. Despite the disappointment of discontinuing our Duchenne program last year, we are advancing more than a dozen... More
